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esponsibility of Xi’Abstract Simple, accurate, sensitive and validated UV spectrophotometric and chemometric methods
were developed for the determination of imidapril hydrochloride (IMD) in the presence of both its alkaline
(AKN) and oxidative (OXI) degradation products and in its pharmaceutical formulation. Method A is the
fourth derivative spectra (D4) which allows the determination of IMD in the presence of both AKN and
OXD, in pure form and in tablets by measuring the peak amplitude at 243.0 nm. Methods B, C and D,
manipulating ratio spectra, were also developed. Method B is the double divisor–ratio difference
spectrophotometric one (DD–RD) by computing the difference between the amplitudes of IMD ratio
spectra at 232 and 256.3 nm. Method C is the double divisor-ﬁrst derivative of ratio spectra method
(DD–DR1) at 243.2 nm, while method D is the mean centering of ratio spectra (MCR) at 288.0 nm.
Methods A, B, C and D could successfully determine IMD in a concentration range of 4.0–32.0 mg/mL.
Methods E and F are principal component regression (PCR) and partial least-squares (PLS), respectively,
for the simultaneous determination of IMD in the presence of both AKN and OXI, in pure form and in its
tablets. The developed methods have the advantage of simultaneous determination of the cited
components without any pre-treatment. The accuracy, precision and linearity ranges of the developedsity. Production and hosting by Elsevier B.V. All rights reserved.
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Stability-indicating spectrophotometric determination of a novel ACE inhibitor 133methods were determined. The results obtained were statistically compared with those of a reported HPLC
method, and there was no signiﬁcant difference between the proposed methods and the reported method
regarding both accuracy and precision.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.Fig. 1 Chemical structure of IMD.1. Introduction
Arterial hypertension is one of the most common cardiovascular
disorders. It is considered to be a social disease due to its high
incidence, contribution in the development of arteriosclerosis and
its clinical forms, coronary disease, cardiac infarction, and cerebral
stroke. The principal action of hypotensive medicines is based on
controlling blood pressure in various pressure points. Renin–
angiotensin–aldosterone system plays an important role in controlling
blood pressure and volume of body ﬂuids. This necessitates searching
for medicines inhibiting the renin–angiotensin activity, including
angiotensin converting enzyme (ACE) inhibitors. These inhibitors are
dipeptides or compounds which are structurally very similar. ACE
inhibitors differ in terms of pharmacokinetic properties and afﬁnity for
ACE. This is related to the strength and time of their activity. At
present, ACE inhibitors are the ﬁrst-choice medicines used in the
treatment of hypertension. They may also be used in the treatment of
ischemia and heart failure. Their active metabolites created as a result
of hydrolysis cause the fall in ACE activity, a decrease in releasing
aldosterone, an increase in the concentration of vaso-dialytic kinins and
prostaglandins and indirectly reducing the synthesis of catecholamines
and general sympathetic activity. This results in the diastole of vessels
and reduction of circulating blood volume, which leads to the drop in
blood pressure and the reduction of peripheral resistance [1].
IMD is a recently developed prodrug-type angiotensin-convert-
ing enzyme (ACE) inhibitor. IMD, with an ethyl ester structure, is
converted into a dicarboxy-type compound (imidaprilat) in the
body. Imidaprilat shows about a 500 times higher activity than the
ester form, IMD [2]. From the literature survey on the subject,
many methods have already been tested including HPLC and GC
methods with the use of MS detector [3–7], chiral LC method [2],
other HPLC methods [8,9], densitometry [1] and spectrophoto-
metric determinations [8,10].
With the intent of improving the quality of the active pharma-
ceutical ingredient (API) and its formulation, there is an increasing
need of separation, identiﬁcation, quantiﬁcation, and characteriza-
tion of the most possible degradation products generated under the
various ICH guidelines for forced degradation [11]. These guide-
lines require the stress testing to be conducted to elucidate the
inherent stability characteristics of the active substance. An ideal
stability-indicating method is one that quantiﬁes the drug and also
resolves its degradation products.
IMD is a novel ACE inhibitor and a non-ofﬁcial pharmacopeial
raw material and therefore, there is no ofﬁcially approved method
neither for its determination in the pharmaceutical dosage forms
nor for its stability or purity assessment: in solid state formula-
tions, as a raw material or in body ﬂuids. Most of the reported
methods for the determination of IMD are based on chromato-
graphic techniques, presenting a relatively high cost and time
consumption. The aim of the present work is to develop accurate,
speciﬁc, reproducible, rapid and less expensive stability-indicating
methods for the determination of IMD in the presence of both its
alkaline and oxidative degradation products for assessment of the
drug stability in its dosage form, which can be performed easilywith adequate software support and thus providing a clear example of
the high resolving power of those techniques. Therefore, in this study,
the proposed methods were ﬁrstly developed for the determination of
IMD in the presence of its possible degradation products, which was
not accomplished by the previously reported methods. This important
feature of the adopted methods can resolve the intact drug in the
presence of more than one degradation product in the same sample.
Other important features of the developed methods are the higher
sensitivity and the wider range of quantitation of IMD offering high
ﬂexibility in the determination of the intact drug at very low and high
concentrations. Also, the application of newly developed spectro-
photometric methods, double divisor–derivative ratio, double divisor–
ratio difference methods and mean centering of ratio spectra, and
multivariate calibration methods: principal component regression
(PCR) and partial least-squares (PLS), was considered and adopted
as stability-indicating methods. The developed methods were
validated as per ICH guidelines [12]. The results obtained by
means of the adopted methods were subsequently statistically
compared. The analytical procedure for both methods comprised
the following stages: (1) validation; (2) evaluation of the key
parameters (i.e., linearity, accuracy and precision); and (3) assay of
IMD content in the pharmaceutical formulation. The chemical
structure of IMD is illustrated in Fig. 1.2. Experimental
2.1. Samples
2.1.1. Pure sample
Imidapril hydrochloride (with certiﬁed purity of 99.80%) was kindly
supplied by SMS Pharmaceuticals Limited, Hyderabad, India.
2.1.2. Pharmaceutical formulation
Tanatrils tablets (Batch no. 8917) labeled to contain 10 mg of
IMD per tablet and manufactured by HIKMA Pharmaceuticals,
Amman–Jordan were purchased from the local market.
2.2. Chemicals and reagents
All chemicals used throughout the work were of spectroscopic
grade. Methanol was purchased from Riedel-de Haen (Seelze,
M.A. Hegazy134Germany). 35.4% of hydrochloric acid (0.1, 3 and 5 M aqueous
solutions) and sodium hydroxide (1 and 5 M aqueous solutions)
were purchased from Merck (Darmstadt, Germany). Thirty percent
of hydrogen peroxide (3% aqueous solution) was purchased from
Fluka (Neu-Ulm, Germany). Two degraded solutions “alkaline
(AKN) and oxidative (OXI)” of IMD, having concentrations of
2.0 mg/mL, were prepared by dissolving 100 mg of the drug in
10 mL of methanol and then mixed with 1 M NaOH and 3%
H2O2, respectively; heating in thermostatic water bath at 80 1C for
12 h and 48 h, respectively. After cooling and neutralizing with
5 M HCl for AKN the volume was obtained by adding methanol
for all the degraded solutions. Complete degradation was ascer-
tained by the disappearance of the intact drug peak at 220 nm in
HPLC using the mobile phase consisting of ACN:0.15% TEA,
pH¼2.2 (40:60, v/v), at a ﬂow rate of 1.5 mL/min. The obtained
degradation products were subjected to infrared spectroscopy (IR)
and mass spectrometry (MS) analyses for subsequent structure
elucidation.2.3. Apparatus
UV–vis spectra were recorded using a Double Beam UV–vis spectro-
photometer, model-T60 (PG Instruments Ltd., UK) with spectral
bandwidth of 0.2 nm connected to an IBM compatible computer and
analyzed using accompanying UVWin Spectrophotometer software
version 5.0.5. pH-meter (Jenway 3310, UK), equipped with combined
glass electrode was used for pH adjustment.
High-performance thin layer chromatography (HPTLC) system
used to ensure complete degradation of IMD drug molecule
consisted of a Camag TLC scanner III S/N 130319 (Camag,
Muttenz, Switzerland) operated with winCATS software version
3.15, Linomat IV autosampler (Camag, Muttenz, Switzerland),
Camag microsyringe 100 mL (Hamilton, Bonaduz, Switzerland),
precoated silica gel aluminum plates 60 F254 (20 cm 10 cm)
with 250 mm thickness (E. Merck, Darmstadt, Germany), and twin
trough Automatic Developing Chamber ADC 2 chamber
20 cm 10 cm (Camag, Muttenz, Switzerland).
Statistical comparison of the proposed methods with a reported
HPLC method was carried out using LaChrom Elites HPLC
system (VWR-Hitachi International GmbH, Darmstadt, Germany),
which comprised L-2130 model pump, equipped with a L-2400
model UV detector and a 20-mL volume injection loop. LaChrom
Elites HPLC system was controlled by EZChrom Elite Software
Chromatography Data System, version 3.3.1 SP1. A Phenomenex
C18 column (250 mm 4.6 mm i.d., 5 mm) was used as the
stationary phase.2.4. Software
All computations were performed in Matlabs version 7.10 [13]. The
PLS procedure was computed using PLS Toolbox version 5.8 [14].2.5. Spectral characteristic
The zero-order (D0) absorption spectra of IMD and its degradates,
AKN and OXI in 0.1 M HCl, were recorded separately over the
range of 200–350 nm using 0.1 M HCl as blank.2.6. Procedure
2.6.1. UV spectrophotometric methods
2.6.1.1. Stock and working solutions. Stock standard solution of
IMD (2.0 mg/mL) was prepared by accurately weighing 100 mg of
pure powder into a 50 mL volumetric ﬂask, dissolved in methanol
and diluted to the required volume with methanol. Stock solutions
of AKN and OXI (2.0 mg/mL) were prepared as previously
mentioned in Section 2.2.
Working standard solution of IMD and working solutions of
AKN and OXI (100 mg/mL; each) were prepared by transferring
5 mL from the stock standard solution of IMD and the stock
solutions of AKN and OXI (2.0 mg/mL; each) into three separate
100-mL volumetric ﬂasks, dissolved in methanol and diluted to the
volume with methanol.
The binary mixture solution of AKN and OXI (3 mg/mL; each),
was used as double divisor (DD).
Aliquots equivalent to 40–320 mg IMD were accurately trans-
ferred from its working standard solution (100 mg/mL) into a series
of 10-mL volumetric ﬂasks. The volume was brought to the mark
with 0.1 M HCl to obtain a ﬁnal concentration range of 4–32 mg/mL.
The zero order absorption spectra of the resulting solutions were
scanned from 200 to 350 nm and stored in the computer.
2.6.1.2. Derivative specrophotometry (D4). Construction of the
calibration curve. The fourth derivative (D4) spectra were
computed using scaling factor¼104 and Δλ¼4 nm. The peak
amplitude at 243.0 nm was measured for IMD, then plotted each
against its corresponding concentration and the regression para-
meters were computed.
Assay of laboratory-prepared mixtures. The absorption spectrum
was recorded for each laboratory-prepared mixture, containing
different ratios of IMD, AKN and OXI against 0.1 M HCl as a
blank and stored in the computer. The peak amplitudes of (D4)
spectra of those laboratory-prepared mixtures were measured at
243.0 nm for IMD determination. The concentrations of IMD were
then calculated from its corresponding regression equation.
2.6.1.3. Double divisor–ratio difference spectrophotometric
(DD–RD) method. Construction of the calibration curve. The
stored spectra of IMD were divided by the spectrum of DD
and stored in the computer as ratio spectra. Calibration curve for
IMD was constructed by plotting the difference between the
amplitudes of ratio spectra at 232.0 nm and 256.3 nm, versus the
corresponding concentration and the regression equation was
computed.
Assay of laboratory-prepared mixtures. The scanned spectra of
the laboratory-prepared mixtures were divided by the absorption
spectrum of DD and stored in the computer, and then the difference
between the amplitudes of ratio spectra at 232.0 nm and 256.3 nm
was computed. The concentration of IMD in the mixtures was
calculated from the corresponding regression equation.
2.6.1.4. Double divisor–derivative ratio spectrophotometric
(DD–DR1) method. Construction of the calibration curve. The
peak amplitude of the ﬁrst derivative of the stored ratio spectra of
IMD at 243.2 nm was differentiated using scaling factor¼10 and
Δλ¼4 nm, then plotted versus the corresponding concentration of
IMD, and the regression equation was computed.
Assay of laboratory-prepared mixtures. The ﬁrst derivative of the
stored ratio spectra of the laboratory-prepared mixtures was
computed. The concentration of IMD in the mixtures was calculated
from the corresponding regression equation at 243.2 nm.
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struction of the calibration curve. The scanned (D0) spectra of
IMD, AKN and OXI were exported to Matlab for subsequent
calculation, then the spectra of IMD were divided by the normal-
ized spectrum of AKN, the obtained ratio spectrum was mean
centered and then the mean centered ratio spectra were divided by
the mean centered normalized vector of AKN/OXI and then mean
centered. The calibration curve for IMD was constructed by
plotting the mean centered values at 288.0 nm, versus the
corresponding concentration of IMD and the regression equation
was computed.
Assay of laboratory-prepared mixtures. The general procedure of
the proposed method mentioned under “Construction of the
calibration curve” was followed. The concentration of IMD was
calculated using the mean centered values at 288.0 nm and the
speciﬁed regression equation.
2.6.2. Chemometric-assisted spectrophotometric methods
2.6.2.1. Stock and working solutions. Stock standard solution of
IMD (2.0 mg/mL) was prepared as mentioned previously in
Section 2.6.1. Stock solutions of AKN and OXI (2.0 mg/mL;
each) were prepared as mentioned previously in Section 2.2.
Working standard solution of IMD (100 mg/mL) was prepared as
mentioned previously in Section 2.6.1. Working solutions of AKN
and OXI (10 mg/mL; each) were prepared by transferring 0.5 mL
from the stock solutions of AKN and OXI (2.0 mg/mL; each) into
two separate 100-mL volumetric ﬂasks, dissolved in and diluted to
the volume with methanol.
Multilevel multifactor design was used for the construction of the
calibration and validation sets [15]. A ﬁve-level, ﬁve-factorTable 1 Concentrations of IMD, AKN and OXI in the
calibration and validation sets for PCR and PLS.
Sample number IMD
(mg/mL)
AKN
(mg/mL)
OXI
(mg/mL)
1 15.0 3.0 3.0
2 15.0 2.4 2.4
3 12.0 2.4 3.6
4 12.0 3.6 2.7
5 18.0 2.7 3.6
6 13.5 3.6 3.0
7 18.0 3.0 2.7
8 15.0 2.7 2.7
9 13.5 2.7 3.3
10 13.5 3.3 3.6
11 16.5 3.6 3.3
12 18.0 3.3 3.0
13 16.5 3.0 3.6
14 15.0 3.6 3.6
15 18.0 3.6 2.4
16 18.0 2.4 3.3
17 12.0 3.3 2.4
18 16.5 2.4 3.0
19 12.0 3.0 3.3
20 15.0 3.3 3.3
21 16.5 3.3 2.7
22 16.5 2.7 2.4
23 13.5 2.4 2.7
24 12.0 2.7 3.0
25 13.5 3.0 2.4
The boldfaced samples are those of the validation set.calibration design was used. The concentrations details are given
in Table 1.
2.6.2.2. Chemometric PCR and PLS methods. Building the
calibration models. A calibration set of seventeen different
laboratory-prepared mixtures of IMD, AKN and OXI in different
ratios was prepared by transferring different aliquots from the
working standard solution of IMD (100 mg/mL) and the working
solutions of AKN (10 mg/mL) and OXI (10 mg/mL) into 10-mL
volumetric ﬂasks and the volumes were completed with 0.1 M
HCl. The absorption spectra of the prepared mixtures were
recorded in the range of 205–305 nm against 0.1 M HCl as blank.
The recorded spectra were then transferred to MATLABs 7.10 for
subsequent data analysis and the calibration models (PCR, PLS)
were constructed.
Assay of external validation set. The absorption spectra of the
validation set that consisted of eight laboratory-prepared mixtures
containing different ratios of IMD, AKN and OXI were recorded
in the range of 205–305 nm. The concentrations of IMD, AKN
and OXI were calculated using the optimized PCR and PLS
calibration models.
2.6.3. Determination of IMD in its pharmaceutical formulation
(Tanatrils tablets)
Ten tablets of Tanatrils were ﬁnely powdered. A portion of the
powdered tablets equivalent to 20 mg of IMD was transferred into
a 25-mL volumetric ﬂask and sonicated for 20 min with 20 mL
methanol, then the volume was completed with the same solvent
and ﬁltered to prepare stock solution, having a concentration of
0.8 mg/mL. Aliquot of 1.5 mL was transferred to 25-mL volu-
metric ﬂasks and the volume was completed with methanol; then
from this solution, second dilutions were made by transferring
aliquots of 2.5, 3.0 and 3.5 mL into three separate 10-mL
volumetric ﬂasks and the volume was completed with 0.1 M
HCl. The general procedures described above for each of the
proposed methods were followed to determine the concentration of
IMD in its pharmaceutical preparation.
2.6.4. Application of standard addition technique
To check the validity of the proposed methods, the standard
addition technique was applied. Three portions of the previously
powdered tablets, each claimed to contain 10 mg of IMD were
accurately weighed and mixed with 8, 10 and 12 mg of the pure
standard IMD, separately. Each spiked sample was transferred to a
25 mL volumetric ﬂask and sonicated for 20 min with 20 mL
methanol then the volume was adjusted with the same solvent and
ﬁltered to obtain three solutions having the concentrations of 0.72,
0.8 and 0.88 mg/mL. Aliquot of 2.5 mL from each spiked solution
was transferred into three separate 25-mL volumetric ﬂasks
and the volume was obtained with methanol. Then from these
solutions, second dilutions were made by transferring aliquot of
2.0 mL from each spiked sample into three separate 10-mL
volumetric ﬂasks and diluting with 0.1 M HCl. The general
procedures described in Sections 2.6.1 and 2.6.2 were then
proceeded.3. Results and discussion
The main task of this work was to establish simple, sensitive and
accurate analytical methods for the simultaneous determination of
IMD in the presence of both its alkaline and oxidative degradation
M.A. Hegazy136products and in its pharmaceutical formulation with satisfactory
precision for good analytical practice (GAP) and to develop
methods of comparable sensitivity and selectivity as chromato-
graphic methods with lower cost and higher speed. Also, to
construct a comparison between the efﬁciency of the proposed
methods and a reported HPLC method.
Upon stress testing of IMD with alkali, the drug underwent
degradation giving a diacid derivative of IMD through hydrolysis
of ester linkage on the basis of the studies of Nishi et al. [2].
Degradation of IMD was also examined upon stress testing using
peroxide. It was noticed that diketopiperazine (DKP) derivative
was produced via oxidation and internal cyclization of IMD as
suggested by Stoﬁk et al. [16]. IMD was exposed to different time
periods (12 h and 48 h) at 80 1C as an accelerated stress test to
carry out complete drug degradation under alkaline and oxidative
conditions, respectively. Complete drug degradation under pre-
viously mentioned conditions was ascertained using previously
developed HPTLC method as presented in Fig. 2.
The assignment of IMD degradation was based on comparison of
IR and MS spectral data for the degradation products with that of the
intact drug as shown in Figs. 3 and 4. IR spectrum of IMD showsFig. 3 IR spectra of IMD, AKN and OXI.
Fig. 2 HPTLC chromatograms of IMD (A), AKN (B) and OXI
(C), using chloroform:ethanol:acetic acid (3:0.5:0.1, by volume) at 220 nm.peaks at 3217 and 3027 cm1, which are assigned to the stretching
vibrations of N–H (the secondary amine) and C–H bands of aromatic
ring. The peaks at 2947 and 2853 cm1 are due to the asymmetric
CH3 and CH2 stretching vibrations, respectively. The peaks at 1751
and 1728 cm1 are attributed to the carbonyl stretching of ester and
carboxylic acid, respectively; while the peak at 1627 cm1 corre-
sponds to the carbonyl stretching of tertiary amide; the peak at
1456 cm1 corresponds to CH2 scissoring; the peak at 1380 cm
1 is
due to C–H bending. The IR spectrum of AKN shows the absence of
the peak at 1751 cm1, which corresponds to the carbonyl stretching
of ester. But the presence of intense and sharp peak at 1725 cm1 is
attributed to the carbonyl stretching of the two carboxylic acid
groups of the diacid derivative of IMD produced through hydrolysis
of ester linkage. The disappearance of IR peaks in OXI spectrum
Fig. 4 MS spectra of IMD, AKN and OXI.
Fig. 5 Schemes of IMD degradation under alkaline (A) and oxidative
(B) conditions.
Fig. 6 Zero order absorption spectra of IMD (12 mg/mL) and of its
degradates, AKN and OXI (3 mg/mL each) using 0.1 M HCl as a solvent.
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group of carboxylic acid), and 1627 cm1 (the carbonyl stretching
of tertiary amide) conﬁrmed the DKP formation. But several new
peaks at 2987, 1738 and 1679 cm1 were observed. The peak at
2987 cm1 was due to the asymmetric CH3 stretching vibration, and
the peaks at 1738 and 1679 cm1 were assigned to the carbonyl
bands of ester and DKP groups, respectively[17].
The mass ion peak of IMD was identiﬁed at m/z 407, while that of
AKN and OXI was at m/z 378 and m/z 387, respectively. Therefore,
one can conclude that carrying out the alkaline hydrolysis and
oxidative degradation of IMD may proceed as shown in Fig. 5.
IMD spectrum suffers a strong overlap with those of its
degradation products, AKN and OXI as shown in Fig. 6, which
prevents direct determination of IMD. Derivative spectrophotometry
(D4), DD–RD, DD–DR1 and MCR were applied to allow the
resolution of IMD. Also, multivariate calibration for the resolution of
these components had been successfully performed using chemo-
metric methods, PCR and PLS.3.1. UV spectrophotometric methods
3.1.1. D4
Derivative spectrophotometry was ﬁrst suggested during the last
decade and soon became a well established technique for the assay
of drug in mixtures and in pharmaceutical dosage forms [18]. It is
a good technique and capable of enhancing the resolution of
overlapped bands [19]. It can be applied for the determination of a
drug in the presence of another by selecting a wavelength where
contribution of one compound is zero or almost zero while the
compound to be determined has a reasonable value.
The fourth derivative (D4) showed that IMD could be deter-
mined by measuring the peak amplitude at 243.0 nm, without any
interference in its measurement from either AKN or OXI; whose
contributions are almost zero, as shown in Fig. 7.
To optimize this method, it was necessary to test the inﬂuence
of variables:(a) Different Δλ values were tried (2–8) where Δλ¼4 showed a
suitable signal to noise ratio and the spectra showed good
resolution.(b) Different scaling factor values were tried (10–104) where
scaling factor 104 was suitable to enlarge the signal of IMD
to facilitate its measurement and to diminish error in reading
signal without any interference from AKN or OXI.A linear correlation was obtained between the peak amplitude
values and the corresponding concentrations for IMD at 243.0 nm.
M.A. Hegazy138The characteristic parameters of the regression equation of the
(D4) method for the determination of IMD are given in Table 2.
3.1.2. DD–RD
This is a newly developed method having the ability for solving
severely overlapped spectra without prior separation mean while it
does not require any sophisticated apparatus or computer programs
[20]. The most striking feature of the DD–RD method is its
simplicity, rapidity and accuracy. The utility of the DD–RD
method is to calculate the unknown concentration of a component
present in a ternary mixture containing the component of interest
and other two unwanted interfering components. For the determi-
nation of concentration of component of interest by the DD–RD
method, the only requirement is the contribution of the three
components at the two selected wavelengths λ1 and λ2 where the
ratio spectrum of the interfering components shows the same
amplitudes (constant) whereas the component of interest shows
signiﬁcant difference in these two amplitude values at these two
selected wavelengths with respect to concentration. The over-
lapped spectra of the cited components suggested that the DD–RD
method was a suitable method for the determination of IMD in the
presence of both its degradates, AKN and OXI.Table 2 Results of regression and assay validation parameters of the
the presence of both AKN and OXI.
Validation parameters D4 DD
Linearity range (mg/mL) 4–32 4–
Slope 0.0413 0.0
SE of slope 0.0003 0.0
Intercept 0.0025 0.0
SE of intercept 0.0048 0.0
Correlation coefﬁcient (r) 0.9998 0.9
SE of regression 0.0060 0.0
SE of residuals 0.0054 0.0
LOD (mg/mL) 0.43 0.4
LOQ (mg/mL) 1.30 1.2
Accuracy (Mean7SD) 100.1470.52 99
Precision (RSD, %)
Intra-day 0.250 0.2
Inter-day 0.891 0.9
Fig. 7 The fourth derivative (D4) spectra of IMD (12 mg/mL) and of
its degradates, AKN and OXI (3 mg/mL, each) using 0.1 M HCl as a
solvent.Ratio difference method began with scanning the zero order
absorption spectra of their laboratory-prepared mixtures (IMD,
AKI and OXI). For determination of IMD, each spectrum of the
previous mixtures was divided by the absorption spectrum of a
solution of binary mixture of AKN and OXI (3 mg/mL; each) as a
double divisor (DD) producing new ratio spectra which represent
IMD/(AKNþOXI)′þconstant, as shown in Fig. 8. The amplitudes
at 232.0 nm and 256.3 nm were selected. The amplitudes at these
two wavelengths were subtracted, so the constant (AKNþOXI)/
(AKNþOXI)′ will be canceled.
To optimize this method, it was necessary to test the inﬂuence of
the divisor and its concentration. Therefore, different concentrations
of AKN and OXI were tried as double divisor. It was found that
changing the concentration had no signiﬁcant effect on the linear
calibration range and the calculated analytical parameters.
The concentration of IMD was calculated using the correspond-
ing regression equation obtained by plotting the difference in
the amplitudes at 232.0 nm and 256.3 nm of the ratio spectra of
IMD/(AKNþOXI)′ against its corresponding concentrations. The
characteristic parameters of the regression equation of the DD–RD
method for the determination of IMD are given in Table 2.developed spectrophotometric methods for determination of IMD in
–RD DD–DR1 MCR
32 4–32 4–32
645 0.0444 2.5018
004 0.0004 0.0194
144 0.0116 0.1989
074 0.0075 0.3612
998 0.9996 0.9997
093 0.0095 0.4525
083 0.0085 0.4047
3 0.63 0.53
9 1.90 1.62
.7871.01 100.9170.79 99.8770.96
54 0.294 0.307
62 0.900 0.958
Fig. 8 Ratio spectra of IMD (12 mg/mL) and of its degradates, AKN
and OXI (3mg/mL each) using DD as double divisor of AKN and OXI
(3 mg/mL each) and 0.1 M HCl as a blank.
Fig. 9 The ﬁrst derivative of the ratio spectra of IMD (12 mg/mL) and
of its degradates, AKN and OXI (3 mg/mL each) using DD as double
divisor of AKN and OXI (3 mg/mL each) and 0.1 M HCl as a blank.
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Another method for resolving ternary mixtures without previous
separation is the DD–DR1 method, which was developed by Dinc
et al. [21]. In this method the absorption spectrum of the mixture is
obtained and divided by the absorption spectrum of a solution of
binary mixture of AKN and OXI (3 mg/mL; each) as a double
divisor (DD) and then the ﬁrst derivative of the ratio spectrum is
obtained. This method permits the determination of IMD in its
mixture at 243.2 nm, as presented in Fig. 9.
To optimize this method, it was necessary to test the inﬂuence
of variables:(a) The divisor and its concentration: different concentrations
of AKN and OXI were tried as double divisor. It was found
that changing the concentration had no signiﬁcant effect
on the linear calibration range and the calculated analytical
parameters.(b) Different Δλ values were tried where Δλ¼4 showed a
suitable signal to noise ratio and the spectra showed good
resolution.(c) Different scaling factor values were tried where scaling factor
10 was suitable to enlarge the signal of IMD to facilitate its
measurement and to diminish errors in reading signal.Fig. 10 Mean centering of ratio spectra of IMD, 4–32 μg/mL in
0.1 M HCl using the spectra of its degradation products as divisor of
AKN and OXI (3 mg/mL each).Calibration curve was constructed at 243.2 nm, representing the
relationship between the peak amplitudes of DD–DR1 and the
corresponding concentrations of IMD. The characteristic para-
meters of the regression equation of the DD-DR1 method for the
determination of IMD are given in Table 2.Fig. 11 Root mean square error of calibration (RMSEC) plot of the
cross validation results of the training set as a function of the number
of principal components used to construct the PCR calibration.3.1.4. MCR
It is a new spectrophotometric method that was developed for
the simultaneous determination of binary and ternary mixtures
without preliminary separation. This method is based on the
mean centering of ratio spectra instead of calculating the derivative
and therefore signal-to-noise ratio is enhanced [22].
As shown in Fig. 6, the absorption spectra of IMD, AKI and
OXI are severely overlapped. So, the absorption spectra of the
standard solutions of IMD with different concentrations were
recorded in the wavelength range of 200–350 nm and divided by
the normalized spectrum of AKN (3 mg/mL) and the obtained ratio
spectra were then divided by the mean centered vector of AKN/
OXI (OXI, 3 mg/mL), then the obtained second ratio spectra were
mean centered as presented in Fig. 10.The effect of divisor concentration on the analytical parameters
such as slope, intercept and correlation coefﬁcient of the calibra-
tion graphs was also tested. Different concentrations of divisor
were used but it was observed that changing the concentration had
no signiﬁcant effect on the linear calibration range and the
calculated analytical parameters. A calibration curve could be
constructed by plotting the amplitude at 288.0 nm against the
corresponding concentrations of IMD. The characteristic para-
meters of the regression equation of the MCR method for the
determination of IMD are given in Table 2.
3.2. Chemometric two-way PCR and PLS methods
The spectral data acquisition was taken with 0.1 nm intervals, thus
producing 1001 data points per spectrum. In order to decrease the
initial number of wavelengths, every 10th wavelength was
selected, thus the produced spectral data matrix has 17 rows
representing different samples and 101 columns representing
wavelengths (17 101). In order to build the PCR and PLS
models, the raw data of the calibration samples were mean
centered [23] as a pre-processing step and the ‘random subsets’
cross-validation method was used [24]; each subset consisted of
six and iterated four times. The appropriate selection of the
number of factors to be used for building the model is crucial
for achieving correct quantitation in PCR and PLS calibrations.
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Haaland and Thomas criteria [25]. The selected model was that
with the smallest number of factors such that root mean square
error of calibration for that model was not signiﬁcantly greater
than root mean square error of calibration from model with an
additional factor. The optimum number of latent variables
described by the constructed models was found to be four factors
for both PCR and PLS as shown in Figs. 11 and 12.Fig. 12 Root mean square error of calibration (RMSEC) plot of the
cross validation results of the training set as a function of the number
of principal components used to construct the PLS calibration.
Table 3 Percentage recoveries of IMD, AKN and OXI in the valida
Sample no. IMD AKN
Conc. (mg/mL) Recovery (%) Conc. (mg/mL)
PCR PLS
1 13.5 99.90 99.94 3.6
2 15.0 99.91 99.89 2.7
3 13.5 100.04 100.02 2.7
4 13.5 99.98 99.99 3.3
5 16.5 99.95 99.95 3.6
6 16.5 99.85 99.86 3.0
7 16.5 100.01 100.07 2.4
8 15.0 100.07 100.07 3.3
Mean 99.96 99.97
RMSEP 0.012 0.012
Table 4 Summary of results obtained by applying the diagnostic to
Validation parameters IMD
PCR
Predicted vs. known concentration plot
1—Slope 0.9979
2—SE of slope 0.003
3—Intercept 0.0260
4—SE of intercept 0.050
6—Correlation coefﬁcient 0.9999
7—SE of regression 0.012
Residual vs. actual concentration plot7error in prediction 0.011In order to assess the predictive ability of each of the developed
models, it was applied on an external validation set for determina-
tion of the three components. The recoveries, mean recoveries and
RMSEP are summarized in Table 3.
The validation of the developed PCR and PLS models was
assessed using several diagnostic tools. The predicted concentra-
tions of the validation samples were plotted against the true
concentration values. This was used to determine whether the
model accounted for the concentration variation in the validation
set. All plots had a slope of nearly one and an intercept close to
zero. The results in Table 4 indicate the high predictive abilities of
the two models.
3.3. Determination of IMD in its pharmaceutical formulation
(Tanatrils tablets)
The suggested methods were successfully applied for determina-
tion of IMD in Tanatrils tablets. The results shown in Table 5 are
satisfactory and with good agreement with the labeled amount.
ICH guidelines [12] for method validation were followed for
validation of the suggested methods.
3.3.1. Linearity
The linearity of the proposed spectrophotometric methods was
evaluated by analyzing six concentrations of IMD ranging from 4
to 32 mg/mL for all of the proposed UV spectrophotometric
methods. Each concentration was repeated three times. The assaytion set using PCR and PLS models.
OXI
Recovery (%) Conc. (mg/mL) Recovery (%)
PCR PLS PCR PLS
100.00 100.00 3.0 100.20 100.11
99.97 99.96 2.7 100.30 100.36
100.02 100.00 3.3 99.91 99.97
99.87 99.88 3.6 100.16 100.11
100.02 100.04 3.3 100.10 100.07
99.85 99.86 3.6 100.48 100.44
99.96 99.95 3.0 99.98 99.86
100.23 100.24 3.3 99.61 99.58
99.99 99.99 100.09 100.06
0.004 0.004 0.009 0.009
ols for model validation of PCR and PLS chemometric methods.
AKN OXI
PLS PCR PLS PCR PLS
0.9985 1.0016 1.0022 1.0034 1.0024
0.004 0.003 0.003 0.011 0.012
0.0180 0.0050 0.0069 0.0079 0.0056
0.054 0.011 0.010 0.037 0.038
0.9999 0.9999 0.9999 0.9991 0.9991
0.013 0.004 0.004 0.009 0.010
0.012 0.004 0.004 0.009 0.009
Table 5 Quantitative determination of IMD in its pharmaceutical preparation by the proposed methods and application of standard
addition technique.
Proposed methods Pharmaceutical preparation Tanatrils tablets
(10 mg IMD per tablet)
Recovery of IMD(%)a
(Mean (%) ± SD) Authentic added (mg/mL) Mean (%)7SD
6.4 8.0 9.6
D4 99.9370.87 99.91 101.11 99.89 100.3070.70
DD–RD 100.1270.91 100.02 101.36 100.25 100.5470.72
DD–DR1 100.0870.81 100.72 101.48 100.31 100.8370.59
MCR 100.0570.69 99.12 101.10 100.28 100.1771.00
PCR 99.8670.70 99.18 100.11 100.03 99.7770.52
PLS 99.9670.70 100.21 100.10 99.05 99.7970.64
aMean of three determinations; standard addition technique; pharmaceutical preparation taken was 8 mg/mL.
Table 6 Determination of IMD in the presence of different proportions of its degradates, AKN and OXI, in laboratory prepared mixtures
by the proposed spectrophotometric methods.
Laboratory prepared mixture Recoveryn of IMD (%)
% Degradation IMD (μg/mL) AKN (μg/mL) OXI (μg/mL) D4 DD–RD DD–DR1 MCR
20 16.0 3.0 1.0 98.24 100.10 100.49 98.24
16.0 1.0 3.0 99.45 100.19 100.49 99.29
16.0 2.0 2.0 99.29 100.19 100.49 99.78
16.0 4.0 0.0 100.50 100.29 100.49 98.84
16.0 0.0 4.0 100.35 100.29 100.49 98.48
50 8.0 6.0 2.0 99.07 98.41 99.45 98.75
8.0 2.0 6.0 99.67 98.61 99.45 100.52
8.0 4.0 4.0 100.28 98.80 99.45 98.21
8.0 8.0 0.0 99.37 99.00 99.45 98.46
8.0 0.0 8.0 101.49 99.19 99.45 99.16
80 4.0 12.0 4.0 101.34 99.51 99.88 99.11
4.0 4.0 12.0 103.16 99.12 99.88 98.15
4.0 8.0 8.0 100.13 99.90 99.88 100.49
4.0 16.0 0.0 102.55 98.73 99.88 100.68
4.0 0.0 16.0 100.74 98.35 99.88 98.91
Mean (%)7SD 100.38 71.33 99.38 70.73 99.9470.44 99.14 70.86
nMean of three determinations.
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viously mentioned (Table 2).
3.3.2. Accuracy
The accuracy of the results was checked by applying the proposed
spectrophotometric methods for the determination of different blind
samples of IMD. The concentrations were obtained from the
corresponding regression equations, from which the percentage
recoveries were calculated with mean percentage recovery (Table 2).
Accuracy of the method was further assured by the use of the
standard addition technique, it was performed by the addition
of known amounts of pure IMD to known concentrations of
the pharmaceutical formulation. The resulting mixtures were
assayed, and the results obtained were compared with theexpected results (Table 5). The good recoveries of the standard
addition technique suggested good accuracy of the proposed
methods.
3.3.3. Precision
3.3.3.1. Repeatability. Three concentrations of IMD (6, 14, and
28 mg/mL) were analyzed three times intra- daily using the proposed
spectrophotometric methods. The percentage recoveries and rela-
tive standard deviation were calculated (Table 2).
3.3.3.2. Intermediate precision. The previous procedures were
repeated inter-daily three times on three different days for the
analysis of the three chosen concentrations. The percentage recov-
eries and relative standard deviation were calculated (Table 2).
Table 7 Statistical comparison between the reported HPLC
method and the adopted methods for the determination of IMD.
Method Mean
(%)
S.D. Variance t-Test a F-test a
Reported
methodb
100.75 0.96 0.912 – –
D4 99.93 0.87 0.751 1.55 1.22
DD–RD 100.12 0.91 0.826 1.16 1.10
DD–DR1 100.08 0.81 0.650 1.32 1.40
MCR 100.05 0.69 0.474 1.45 1.92
PCR 99.86 0.70 0.485 1.85 1.88
PLS 99.96 0.70 0.491 1.63 1.86
aThe theoretical values of t and F at P¼0.05 are 2.23 and 5.05,
respectively (n¼6).
bHPLC method using C18 column, ﬂow rate of 1.0 mL/min,
mobile phase composed of acetonitrile–methanol–phosphate buffer,
pH 2.0 (60:10:30, v/v/v) and UV detection at 254 nm.
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The calibration range was established through considerations of
the practical range necessary according to adherence to Beer's law
and the concentration of IMD present in the pharmaceutical
preparations to give accurate, precise and linear results (Table 2).
3.3.5. Detection and quantitation limits
According to the ICH recommendations [12], the approach based
on the SD of the response and the slope was used for determining
the limits of detection (LOD) and quantitation (LOQ) (Table 2).
LOD¼ 3:3 SD of the response=slope
LOQ¼ 10 SD of the response=slope
3.3.6. Speciﬁcity
Speciﬁcity of the proposed spectrophotometric methods was
achieved by the analysis of different laboratory prepared mixtures
of IMD and its degradation products, AKN and OXI, within the
linearity range. Satisfactory results are shown in Table 6.
Table 7 shows statistical comparison of the results obtained by
the proposed methods and the reported HPLC method by Stanisz
et al. [8]. The calculated t and F values are less than the theoretical
ones indicating that there is no signiﬁcant difference between the
proposed methods and the reported HPLC method with respect to
accuracy and precision.4. Conclusion
The present work is concerned with the determination of IMD in
the presence of both its alkaline and oxidative degradation
products, in pure form or in its pharmaceutical formulation. The
proposed spectrophotometric and chemometric methods are
considered to be simple, convenient, less time consuming and
economic stability-indicating methods compared to other pub-
lished LC methods. The suggested methods showed high sensi-
tivity, accuracy, reproducibility and speciﬁcity. These methods can
be used as stability-indicating methods and can determine IMD in
its tablets without interference from excipients. Moreover, the
adopted methods are inexpensive and do not require sophisticated
techniques or instruments. They can be considered useful andpromising for developing routine quality control analysis of
pharmaceuticals without any preliminary separation step. They
are valid for application in laboratories lacking liquid chromato-
graphic instruments.
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